<p>Lisanti Capital Growth LLC 在第二季度削减了其在 Apellis Pharmaceuticals, Inc.（NASDAQ:APLS - Free Report）的持股，根据该公司最新向 SEC 提交的 Form 13F 文件，该基金在本季度出售了 64325 股，持有公司股票 24885 股。Lisanti Capital Growth LLC 在最新报告期结束时持有的 Apellis Pharmaceuticals 股票价值 95.5 万美元。</p>
<ul>
<li>Beam Therapeutics 因基因疗法许可支付而大幅上涨</li>
</ul>
<p>其他几家对冲基金和机构投资者最近也增加或减少了对 APLS 的持股。查尔斯·施瓦布投资管理公司（Charles Schwab Investment Management Inc.）在第四季度增加了对 Apellis Pharmaceuticals 股票的持股比例，增长了 2.8%。查尔斯·施瓦布投资管理公司现在拥有公司股票 904409 股，价值 5413.8 万美元，在此期间购买了 25052 股。挪威中央银行在第四季度以 5664 万美元的价格收购了 Apellis Pharmaceuticals 的新头寸。Great Lakes Advisors LLC 在第四季度以 1246.1 万美元的价格购入了 Apellis Pharmaceuticals 的新头寸。Mirae Asset Global Investments Co. Ltd.在第一季度购入了 Apellis Pharmaceuticals 股票 321.8 万美元。最后，Bellevue Group AG 在第四季度将其在 Apellis Pharmaceuticals 的持股比例提高了 3.5%。Bellevue Group AG 现在拥有公司股票 821800 股，价值 4919.3 万美元，在上一季度购入了 27959 股。96.29% 的股份由机构投资者和对冲基金持有。</p>
<h2>分析师的升级和降级</h2>
<p>APLS 最近成为几份研究报告的主题。富国银行（Wells Fargo &amp; Company）将 Apellis Pharmaceuticals 的目标股价从 57.00 美元降至 48.00 美元，并为该公司设定了 “持平” 评级，日期为 2019 年 5 月 23 日。高盛集团（The Goldman Sachs Group）将 Apellis Pharmaceuticals 的目标股价从 66.00 美元上调至 74.00 美元，并在 2019 年 8 月 9 日的研究报告中为该股票设定了 “买入” 评级。派珀·桑德勒（Piper Sandler）在 2019 年 5 月 31 日的研究报告中开始对 Apellis Pharmaceuticals 进行覆盖。他们为该公司设定了 “中性” 评级和 46.00 美元的目标股价。瑞银集团（UBS Group）将 Apellis Pharmaceuticals 的目标股价从 85.00 美元降至 83.00 美元，并在 2019 年 8 月 9 日的研究报告中为该股票设定了 “买入” 评级。最后，摩根大通（JPMorgan Chase &amp; Co.）将 Apellis Pharmaceuticals 的目标股价从 72.00 美元降至 64.00 美元，并在 2019 年 8 月 13 日的研究报告中为该公司设定了 “超配” 评级。四位投资分析师对该股票进行了持有评级，十位给出了买入评级，一位给出了强烈买入评级。根据 MarketBeat 的数据，该公司的共识评级为 “中等买入”，目标股价为 72.13 美元。</p>
<p><strong>查看我们对 APLS 的最新股票分析</strong></p>
<h2>Apellis Pharmaceuticals 的内部交易</h2>
<p>在其他 Apellis Pharmaceuticals 的消息中，董事 A. Sinclair Dunlop 于 2019 年 6 月 21 日的交易中出售了该公司的 37000 股股票。这些股票的平均价格为 39.24 美元，总交易额为 145.188 万美元。交易后，该董事在公司中直接持有 136998 股股票，价值 537.58 万美元。该交易已在提交给证券交易委员会的文件中披露，可在此链接中查看。公司内部持有 6.80% 的股份。</p>
<h2>Apellis Pharmaceuticals 股票表现</h2>
<p>APLS 股票周五在午盘交易中上涨 0.18 美元，达到 38.90 美元。公司股票交易量为 636078 股，相比其平均交易量 1355396 股有所减少。该公司的资产负债比为 1.73，流动比率为 5.08，速动比率为 4.18。Apellis Pharmaceuticals, Inc.的 52 周最低价为 33.49 美元，52 周最高价为 73.80 美元。公司的 50 天移动平均价格为 37.94 美元，200 天移动平均价格为 46.71 美元。</p>
<p>Apellis Pharmaceuticals（NASDAQ:APLS - Get Free Report）于 2019 年 8 月 1 日发布了最新的财报。该公司在本季度报告的每股收益（EPS）为-0.30 美元，高于分析师预期的-0.33 美元。本季度公司营收为 1.997 亿美元，超过分析师预期的 1.9089 亿美元。Apellis Pharmaceuticals 的净资产回报率为-138.32%，净利润率为-52.99%。公司本季度的营收同比增长 110.2%。在去年同期的同一季度，公司每股亏损为-1.02 美元。分析师平均预计，Apellis Pharmaceuticals, Inc.今年将实现每股-1.28 美元的亏损。</p>
<h2>Apellis Pharmaceuticals 简介（免费报告）</h2>
<p>Apellis Pharmaceuticals, Inc.是一家商业化阶段的生物制药公司，专注于通过抑制补体系统来发现、开发和商业化治疗化合物，用于自身免疫性和炎症性疾病。该公司提供 EMPAVELI 用于治疗夜间血红蛋白尿、C3 肾小球病和免疫复合物膜增殖性肾小球肾炎，以及用于治疗造血干细胞移植相关性血栓性微血管病的药物；SYFOVRE 用于治疗由年龄相关性黄斑变性引起的地理性萎缩和地理性萎缩（GA）。</p>
<h2>精选故事</h2>
<ul>
<li>我们喜欢的五只股票，比 Apellis Pharmaceuticals 更好</li>
<li>在购买股票之前如何评估一家公司</li>
<li>不要忽视康宝食品：这是可能推动其股价的因素</li>
<li>投资优先股与普通股</li>
<li>比股票交易所滑坡——为什么这可能是你的下一个大赢家</li>
<li>什么是纳斯达克证券交易所？</li>
<li>MarketBeat 周评 - 8/26 - 8/30</li>
</ul>
<p><strong>想知道其他对 Apellis Pharmaceuticals（纳斯达克股票代码：APLS - 免费报告）持有的对冲基金是什么吗？</strong> 访问 HoldingsChannel.com 获取最新的 13F 申报和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBMUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBMUw"/></p>
<p>_这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快速、最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</p>
<p>→ 曾预测拜登退出竞选的前白宫顾问做出了惊人的新预测（来自 Paradigm Press）(广告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzM5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzM5"/></p>
<h2>现在是否值得投资$1,000 购买 Apellis Pharmaceuticals？</h2>
<p>在考虑投资 Apellis Pharmaceuticals 之前，您可能想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街评级最高、表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉客户现在就买入的股票... 而 Apellis Pharmaceuticals 并不在名单上。</p>
<p>尽管 Apellis Pharmaceuticals 目前在分析师中拥有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

APLS

<p>Lisanti Capital Growth LLC 在第二季度将其在 Apellis Pharmaceuticals（NASDAQ:APLS）的持股减少了 72.1％，卖出 64,325 股，保留 24,885 股。其他机构投资者也调整了他们的持股。分析师对 APLS 的意见不一，有四个持有评级，十个买入评级，共识目标价为 54.13 美元。内部交易包括董事 A. Sinclair Dunlop 出售了 37,000 股。APLS 股价周五上涨至 12.90 美元，52 周范围为 5.49 美元至 18.80 美元，公司报告第二季度的每股收益为-0.30 美元，超过了预期</p>

<p>Lisanti Capital Growth LLC trimmed its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 72.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 24,885 shares of the company's stock after selling 64,325 shares during the quarter. Lisanti Capital Growth LLC's holdings in Apellis Pharmaceuticals were worth $955,000 at the end of the most recent reporting period.</p>
<ul>
<li>Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments</li>
</ul>
<div class="lb-trans"><p>Lisanti Capital Growth LLC 在第二季度削减了其在 Apellis Pharmaceuticals, Inc.（NASDAQ:APLS - Free Report）的持股，根据该公司最新向 SEC 提交的 Form 13F 文件，该基金在本季度出售了 64325 股，持有公司股票 24885 股。Lisanti Capital Growth LLC 在最新报告期结束时持有的 Apellis Pharmaceuticals 股票价值 95.5 万美元。</p>
<ul>
<li>Beam Therapeutics 因基因疗法许可支付而大幅上涨</li>
</ul>
</div><p>Several other hedge funds and other institutional investors also recently added to or reduced their stakes in APLS. Charles Schwab Investment Management Inc. grew its stake in shares of Apellis Pharmaceuticals by 2.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 904,409 shares of the company's stock worth $54,138,000 after purchasing an additional 25,052 shares during the period. Norges Bank acquired a new position in Apellis Pharmaceuticals in the 4th quarter valued at $56,640,000. Great Lakes Advisors LLC purchased a new position in Apellis Pharmaceuticals in the 4th quarter valued at $12,461,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Apellis Pharmaceuticals in the first quarter worth about $3,218,000. Finally, Bellevue Group AG boosted its position in Apellis Pharmaceuticals by 3.5% during the fourth quarter. Bellevue Group AG now owns 821,800 shares of the company's stock worth $49,193,000 after acquiring an additional 27,959 shares during the last quarter. 96.29% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他几家对冲基金和机构投资者最近也增加或减少了对 APLS 的持股。查尔斯·施瓦布投资管理公司（Charles Schwab Investment Management Inc.）在第四季度增加了对 Apellis Pharmaceuticals 股票的持股比例，增长了 2.8%。查尔斯·施瓦布投资管理公司现在拥有公司股票 904409 股，价值 5413.8 万美元，在此期间购买了 25052 股。挪威中央银行在第四季度以 5664 万美元的价格收购了 Apellis Pharmaceuticals 的新头寸。Great Lakes Advisors LLC 在第四季度以 1246.1 万美元的价格购入了 Apellis Pharmaceuticals 的新头寸。Mirae Asset Global Investments Co. Ltd.在第一季度购入了 Apellis Pharmaceuticals 股票 321.8 万美元。最后，Bellevue Group AG 在第四季度将其在 Apellis Pharmaceuticals 的持股比例提高了 3.5%。Bellevue Group AG 现在拥有公司股票 821800 股，价值 4919.3 万美元，在上一季度购入了 27959 股。96.29% 的股份由机构投资者和对冲基金持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师的升级和降级</h2>
</div><p>APLS has been the subject of several recent research reports. Wells Fargo &amp; Company cut their price target on Apellis Pharmaceuticals from $57.00 to $48.00 and set an &#34;equal weight&#34; rating for the company in a report on Thursday, May 23rd. The Goldman Sachs Group lifted their target price on shares of Apellis Pharmaceuticals from $66.00 to $74.00 and gave the stock a &#34;buy&#34; rating in a research note on Friday, August 9th. Piper Sandler initiated coverage on Apellis Pharmaceuticals in a research note on Friday, May 31st. They set a &#34;neutral&#34; rating and a $46.00 target price for the company. UBS Group decreased their target price on shares of Apellis Pharmaceuticals from $85.00 to $83.00 and set a &#34;buy&#34; rating on the stock in a research report on Friday, August 9th. Finally, JPMorgan Chase &amp; Co. dropped their target price on Apellis Pharmaceuticals from $72.00 to $64.00 and set an &#34;overweight&#34; rating for the company in a research report on Tuesday, August 13th. Four investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $72.13.</p>
<ul>
<li>Are Small Caps a Harbinger of Market Declines?</li>
</ul>
<div class="lb-trans"><p>APLS 最近成为几份研究报告的主题。富国银行（Wells Fargo &amp; Company）将 Apellis Pharmaceuticals 的目标股价从 57.00 美元降至 48.00 美元，并为该公司设定了 “持平” 评级，日期为 2019 年 5 月 23 日。高盛集团（The Goldman Sachs Group）将 Apellis Pharmaceuticals 的目标股价从 66.00 美元上调至 74.00 美元，并在 2019 年 8 月 9 日的研究报告中为该股票设定了 “买入” 评级。派珀·桑德勒（Piper Sandler）在 2019 年 5 月 31 日的研究报告中开始对 Apellis Pharmaceuticals 进行覆盖。他们为该公司设定了 “中性” 评级和 46.00 美元的目标股价。瑞银集团（UBS Group）将 Apellis Pharmaceuticals 的目标股价从 85.00 美元降至 83.00 美元，并在 2019 年 8 月 9 日的研究报告中为该股票设定了 “买入” 评级。最后，摩根大通（JPMorgan Chase &amp; Co.）将 Apellis Pharmaceuticals 的目标股价从 72.00 美元降至 64.00 美元，并在 2019 年 8 月 13 日的研究报告中为该公司设定了 “超配” 评级。四位投资分析师对该股票进行了持有评级，十位给出了买入评级，一位给出了强烈买入评级。根据 MarketBeat 的数据，该公司的共识评级为 “中等买入”，目标股价为 72.13 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on APLS</strong></p>
<div class="lb-trans"><p><strong>查看我们对 APLS 的最新股票分析</strong></p>
</div><h2>Insider Transactions at Apellis Pharmaceuticals</h2>
<div class="lb-trans"><h2>Apellis Pharmaceuticals 的内部交易</h2>
</div><p>In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 37,000 shares of the company's stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $39.24, for a total transaction of $1,451,880.00. Following the transaction, the director now directly owns 136,998 shares in the company, valued at $5,375,801.52. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. Corporate insiders own 6.80% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Apellis Pharmaceuticals 的消息中，董事 A. Sinclair Dunlop 于 2019 年 6 月 21 日的交易中出售了该公司的 37000 股股票。这些股票的平均价格为 39.24 美元，总交易额为 145.188 万美元。交易后，该董事在公司中直接持有 136998 股股票，价值 537.58 万美元。该交易已在提交给证券交易委员会的文件中披露，可在此链接中查看。公司内部持有 6.80% 的股份。</p>
</div><h2>Apellis Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Apellis Pharmaceuticals 股票表现</h2>
</div><p>Shares of APLS traded up $0.18 during mid-day trading on Friday, hitting $38.90. 636,078 shares of the company's stock were exchanged, compared to its average volume of 1,355,396. The company has a debt-to-equity ratio of 1.73, a current ratio of 5.08 and a quick ratio of 4.18. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $33.49 and a fifty-two week high of $73.80. The business's 50 day moving average is $37.94 and its two-hundred day moving average is $46.71.</p>
<div class="lb-trans"><p>APLS 股票周五在午盘交易中上涨 0.18 美元，达到 38.90 美元。公司股票交易量为 636078 股，相比其平均交易量 1355396 股有所减少。该公司的资产负债比为 1.73，流动比率为 5.08，速动比率为 4.18。Apellis Pharmaceuticals, Inc.的 52 周最低价为 33.49 美元，52 周最高价为 73.80 美元。公司的 50 天移动平均价格为 37.94 美元，200 天移动平均价格为 46.71 美元。</p>
</div><p>Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its earnings results on Thursday, August 1st. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.03. The business had revenue of $199.70 million for the quarter, compared to analyst estimates of $190.89 million. Apellis Pharmaceuticals had a negative return on equity of 138.32% and a negative net margin of 52.99%. The company's revenue for the quarter was up 110.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.02) earnings per share. On average, analysts expect that Apellis Pharmaceuticals, Inc. will post -1.28 earnings per share for the current year.</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals（NASDAQ:APLS - Get Free Report）于 2019 年 8 月 1 日发布了最新的财报。该公司在本季度报告的每股收益（EPS）为-0.30 美元，高于分析师预期的-0.33 美元。本季度公司营收为 1.997 亿美元，超过分析师预期的 1.9089 亿美元。Apellis Pharmaceuticals 的净资产回报率为-138.32%，净利润率为-52.99%。公司本季度的营收同比增长 110.2%。在去年同期的同一季度，公司每股亏损为-1.02 美元。分析师平均预计，Apellis Pharmaceuticals, Inc.今年将实现每股-1.28 美元的亏损。</p>
</div><h2>Apellis Pharmaceuticals Profile (Free Report)</h2>
<div class="lb-trans"><h2>Apellis Pharmaceuticals 简介（免费报告）</h2>
</div><p>Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals, Inc.是一家商业化阶段的生物制药公司，专注于通过抑制补体系统来发现、开发和商业化治疗化合物，用于自身免疫性和炎症性疾病。该公司提供 EMPAVELI 用于治疗夜间血红蛋白尿、C3 肾小球病和免疫复合物膜增殖性肾小球肾炎，以及用于治疗造血干细胞移植相关性血栓性微血管病的药物；SYFOVRE 用于治疗由年龄相关性黄斑变性引起的地理性萎缩和地理性萎缩（GA）。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Apellis Pharmaceuticals</li>
<li>How to Evaluate a Stock Before Buying</li>
<li>Don’t Overlook Campbell Soup: Here’s What Could Drive Its Stock</li>
<li>Investing In Preferred Stock vs. Common Stock</li>
<li>Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win</li>
<li>What is the NASDAQ Stock Exchange?</li>
<li>MarketBeat Week in Review – 8/26 - 8/30</li>
</ul>
<div class="lb-trans"><h2>精选故事</h2>
<ul>
<li>我们喜欢的五只股票，比 Apellis Pharmaceuticals 更好</li>
<li>在购买股票之前如何评估一家公司</li>
<li>不要忽视康宝食品：这是可能推动其股价的因素</li>
<li>投资优先股与普通股</li>
<li>比股票交易所滑坡——为什么这可能是你的下一个大赢家</li>
<li>什么是纳斯达克证券交易所？</li>
<li>MarketBeat 周评 - 8/26 - 8/30</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding APLS?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对 Apellis Pharmaceuticals（纳斯达克股票代码：APLS - 免费报告）持有的对冲基金是什么吗？</strong> 访问 HoldingsChannel.com 获取最新的 13F 申报和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBMUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=APLS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p>_这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快速、最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</p>
</div><p>→ Ex WH Advisor Who Predicted Biden Leaving Race Makes Startling New Prediction (From Paradigm Press)(Ad)</p>
<div class="lb-trans"><p>→ 曾预测拜登退出竞选的前白宫顾问做出了惊人的新预测（来自 Paradigm Press）(广告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzM5" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9339&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Apellis Pharmaceuticals right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资$1,000 购买 Apellis Pharmaceuticals？</h2>
</div><p>Before you consider Apellis Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Apellis Pharmaceuticals 之前，您可能想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apellis Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街评级最高、表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉客户现在就买入的股票... 而 Apellis Pharmaceuticals 并不在名单上。</p>
</div><p>While Apellis Pharmaceuticals currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Apellis Pharmaceuticals 目前在分析师中拥有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Apellis Pharmaceuticals 公司（纳斯达克股票代码：APLS）的股份被 Lisanti Capital Growth LLC 出售